Seattle Genetics Inks $200M Licensing Deal with Pfizer

January 2011
Bioworld Week;1/10/2011, Vol. 19 Issue 2, p5
The article focuses on the 200 million dollars licensing deal with Seattle Genetics Inc. and Pfizer Inc. for the Seagen's antibody-drug conjugate


Related Articles

  • Seattle Genetics Inks $200M Licensing Deal with Pfizer. Shaffer, Catherine // BioWorld Today;1/7/2011, Vol. 22 Issue 5, p1 

    The article reports on a licensing deal signed by Pfizer Inc. with Seattle Genetics Inc. (Seagen) for access to Seattle's antibody-drug conjugate (ADC). The 200 million dollar deal was reportedly closed at a significant premium over a similar deal with GlaxoSmithKline plc in December 2009. It...

  • SEATTLE GENETICS LICENSES PROACTA'S CELL-KILLING DRUGS.  // Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1 

    Deals with the licensing of cell-killing drugs from Proacta Therapeutics by Seattle Genetics Inc. Plans of Seattle Genetics for the drugs; Signficance of the agreement to Seattle Genetics; Background on Proacta Therapeutics.

  • Pfizer Takes New Direction With Protalix Pact.  // Chain Drug Review;12/7/2009, Vol. 31 Issue 21, p75 

    The article reports on the agreement among Protalix Ltd. and Pfizer Inc. to market expensive medications for the treatment of Gaucher's disease.

  • Bayer and Seattle Genetics form tumor treatment alliance.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p15 

    Announces that Bayer Pharmaceutical Corp. has licensed anticancer biotechnology firm Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology to fight tumors by linking cell-killing drugs to antibodies. Terms of the agreement; Seattle Genetics' development of improved ADC...

  • Seattle, Genentech extend antibody agreement.  // PharmaWatch: Biotechnology;May2007, Vol. 6 Issue 5, p13 

    The article provides updates on the alliance of Genentech company and Seattle Genetics Inc. in the U.S. According to reports, Genentech has extended its antibody-drug conjugate agreement with Seattle Genetics and will have exclusive licenses to specific targets and use of Seattle's antibody-drug...

  • Pfizer licenses gene for possible AMD therapy.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p8 

    The article reports on the acquisition of Pfizer Inc. of the worldwide license to a novel human gene with Quark Biotech Inc. in the U.S. Under the deal, the former will develop the gene called RTP-801, and molecules that modify it that could have the potential to treat neovascular age-related...

  • XOMA Gets $30 Million Upfront In Pfizer Technology Deal. Morrison, Trista // BioWorld Today;8/29/2007, Vol. 18 Issue 168, p1 

    The article reports that the shares of antibody company XOMA Ltd. have increased by 18% after it unveiled a license agreement that provides Pfizer Inc. with non-exclusive access to XOMA's patented bacterial cell expression (BCE) technology. XOMA will get a $30 million upfront cash payment in...

  • Finding New Drugs Through Alliances. Koppal, Tanuja // Drug Discovery & Development;Dec2003, Vol. 6 Issue 12, p22 

    Discusses the investment of Pfizer in file enrichment programs to search for drug-like compounds in the U.S. Development of pharmaceutical products through alliances; Negotiation of licensing deals; Value of the portfolio of external collaborations. INSET: Starting out right.

  • Pfizer Taps pSivida Delivery: Up To $165M.  // Bioworld Week;4/9/2007, Vol. 15 Issue 15, p4 

    The article reports on the licensing agreement that takes place between pSivida Ltd. of Perth, Australia, and Pfizer Inc. of New York. The deal, which is set to produce $165 million, will allow pSivida to use sustained-release drug delivery including its Medidur in ophthalmic applications. As...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics